{"schema_version":"secwatch.filing_event.v1","accession":"0001157523-23-001145","form_type":"8-K","ticker":"USNA","cik":"0000896264","company_name":"USANA HEALTH SCIENCES INC","filed_at":"2023-07-25T23:59:59+00:00","discovered_at":"2026-05-14T18:03:36.955523+00:00","generated_at":"2026-06-13T03:47:40.131326+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"USANA Q2 net sales $238M (-10% YoY), EPS $0.89; FY2023 guidance raised at low end","bullets":["Q2 net sales $238M, down 10% YoY; diluted EPS $0.89 vs $1.00.","Active customers 487k, down 13% YoY; sequential rise in mainland China customers (+5%).","FY2023 guidance: net sales $900-950M (prev $875-950M), EPS $2.65-3.30 (prev $2.40-3.30).","Greater China net sales $129M, +4% sequential; mainland China local-currency sales +10% QoQ.","Plans to open 25th market, India, in late 2023; first new market since 2018."],"urls":{"canonical":"https://secwatch.observer/filing/0001157523-23-001145","json":"https://secwatch.observer/filing/0001157523-23-001145.json","markdown":"https://secwatch.observer/filing/0001157523-23-001145.md","text":"https://secwatch.observer/filing/0001157523-23-001145.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/896264/000115752323001145/0001157523-23-001145-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/896264/000115752323001145/a53479151.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-13T03:47:40.131326+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"02472b89aebb3cea1606a3c98e7c6393404fbb90","claim":"USANA HEALTH SCIENCES INC reported fiscal year 2023 results: revenue $900 to $950 million, EPS $2.65 to $3.30. Guidance raised.","evidence_excerpt":"Fiscal 2023 net sales and diluted EPS guidance updated to $900 to $950 million and $2.65 to $3.30, respectively, from $875 million to $950 million and $2.40 to $3.30.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/896264/000115752323001145/0001157523-23-001145-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"fiscal year 2023"},{"label":"Revenue","value":"$900 to $950 million"},{"label":"EPS","value":"$2.65 to $3.30"},{"label":"Guidance","value":"raised"},{"label":"Result","value":"guidance update"}],"fact_type":"earnings_release"},{"claim_id":"e14f81429c1c40701cdb2e77214aa1560db58425","claim":"USANA HEALTH SCIENCES INC reported second quarter ended July 1, 2023 results: revenue $238 million, EPS $0.89.","evidence_excerpt":"Second quarter net sales were $238 million versus $264 million during the second quarter of 2022. Second quarter diluted EPS was $0.89 as compared with $1.00 during the second quarter of 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/896264/000115752323001145/0001157523-23-001145-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"second quarter ended July 1, 2023"},{"label":"Revenue","value":"$238 million"},{"label":"EPS","value":"$0.89"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}